Celldex Therapeutics Stock Quote CLDX - Stock Price, News, Charts, Message Board, Trades

Professional-Grade Tools, for Individual Investors.

Premium

Current Price

39.35

Bid

39.31

Ask

39.35

Volume

307,505

38.195 Day's Range 39.64

22.11 52 Week Range 53.18

Market Cap

2.594B

Previous Close

38.84

Open

38.38

Last Trade

39.35

Last Trade Time

15:54:48

Financial Volume

$ 11,981,944

VWAP

38.965

Average Volume (3m)

621,710

Shares Outstanding

65,910,548

Dividend Yield

PE Ratio

-18.35

Earnings Per Share (EPS)

-2.15

Revenue

6.88M

Net Profit

-141.43M

Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung c... Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527. Show more

Sector

In Vitro,in Vivo Diagnostics

Industry

In Vitro,in Vivo Diagnostics

Website

www.celldex.com

Headquarters

Wilmington, Delaware, USA

Founded

1970

Celldex Therapeutics Inc is listed in the In Vitro,in Vivo Diagnostics sector of the NASDAQ with ticker CLDX. The last closing price for Celldex Therapeutics was $38.84. Over the last year, Celldex Therapeutics shares have traded in a share price range of $ 22.11 to $ 53.18.

Celldex Therapeutics currently has 65,910,548 shares outstanding. The market capitalization of Celldex Therapeutics is $2.56 billion. Celldex Therapeutics has a price to earnings ratio (PE ratio) of -18.35.

Celldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous Urticaria

- EMBARQ-CSU1 and EMBARQ-CSU 2 will enroll more than 1800 patients suffering from CSU -- Studies include both biologic naïve and experienced patients - HAMPTON, N.J., July 16, 2024 (GLOBE...

Form 4 - Statement of changes in beneficial ownership of securities

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.24	-0.606213690326	39.59	39.88	35.81	597738	37.85017591	CS
4	3.37	9.36631461923	35.98	40.695	34.78	553283	37.91025117	CS
12	1.86	4.96132301947	37.49	43.35	32.25	621710	37.1921532	CS
26	0.25	0.639386189258	39.1	53.18	32.25	780757	40.69691111	CS
52	2.94	8.07470475144	36.41	53.18	22.11	709207	36.14891538	CS
156	-3.58	-8.33915676683	42.93	57.2	19.85	609597	35.8764579	CS
260	37.27	1791.82692308	2.08	57.2	1.5	698439	25.44643635	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
AAGRAfrican Agriculture Holdings Inc	$ 0.00 (0.00%)	0
AADRAdvisorShares Dorsey Wright ADR ETF	$ 0.00 (0.00%)	0
AADIAadi Bioscience Inc	$ 0.00 (0.00%)	0
AACIArmada Acquisition Corporation I	$ 0.00 (0.00%)	0
AACGATA Creativity Global	$ 0.00 (0.00%)	0
AAGRAfrican Agriculture Holdings Inc	$ 0.00 (0.00%)	0
AADRAdvisorShares Dorsey Wright ADR ETF	$ 0.00 (0.00%)	0
AADIAadi Bioscience Inc	$ 0.00 (0.00%)	0
AACIArmada Acquisition Corporation I	$ 0.00 (0.00%)	0
AACGATA Creativity Global	$ 0.00 (0.00%)	0
AAGRAfrican Agriculture Holdings Inc	$ 0.00 (0.00%)	0
AADRAdvisorShares Dorsey Wright ADR ETF	$ 0.00 (0.00%)	0
AADIAadi Bioscience Inc	$ 0.00 (0.00%)	0
AACIArmada Acquisition Corporation I	$ 0.00 (0.00%)	0
AACGATA Creativity Global	$ 0.00 (0.00%)	0